Gore Excluder 低通透性内假体治疗肾下腹主动脉瘤的长期结果
该回顾性多中心研究分析了2004至2017年间四家荷兰医院使用 Gore Excluder 低通透性(LP)内假体治疗肾下腹主动脉瘤的514例患者,中位随访5.0年。结果显示1年、5年、10年生存率分别为94.0%、73.0%、37.0%,免于再干预率分别为89.0%、79.0%、71.0%。37.9%的患者在说明书(IFU)外使用,其10年再干预率显著高于IFU内使用(36.0% vs 25.0%,p = .044);1年瘤囊增长与更差生存显著相关(p = .047)。
要点
- 10年生存率37.0%,免于再干预率71.0%,37.9%患者IFU外使用致再干预显著增加(36.0% vs 25.0%,p = .044)。
- 1年瘤囊增长与更差生存显著相关(p = .047),随访中7例(1.4%)发生破裂。
- 15年内各型内漏发生率:1a型5.3%、1b型3.1%、3型1.9%、4型0.2%、2型35.6%。
核心结论
- 该多中心真实世界数据显示,尽管37.9%患者IFU外使用,Gore Excluder LP内假体仍具有稳健的长期生存率和再干预率,4型内漏罕见。
- IFU外使用显著增加再干预率;1年瘤囊增长与统计学显著更差的生存相关。
研究设计与样本
- 回顾性分析2004至2017年间四家荷兰高容量医院使用Gore Excluder LP治疗肾下腹主动脉瘤的患者。
- 共纳入514例患者,中位(IQR)随访5.0(2.9,6.9)年。
主要发现
- 1年、5年、10年生存率分别为94.0%、73.0%、37.0%;免于再干预率分别为89.0%、79.0%、71.0%。
- 37.9%患者IFU外使用,其10年再干预率显著高于IFU内使用(36.0% vs 25.0%,p = .044)。
- 瘤囊1年、5年、10年退缩率分别为53.5%、65.8%、77.8%,增长率分别为9.8%、14.3%、22.2%。
- 1年瘤囊增长患者生存显著更差(p = .047);随访期间7例(1.4%)发生动脉瘤破裂。
- 15年内1a型内漏5.3%、1b型3.1%、3型1.9%、4型0.2%、2型35.6%。
关键数值与推荐
- IFU外使用10年再干预率36.0% vs IFU内使用25.0%(p = .044)。
- 1年瘤囊增长患者生存显著更差(p = .047)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This study evaluated the long term outcomes of endovascular aneurysm repair using the Gore Excluder Low Permeability (LP) endoprosthesis across high volume Dutch hospitals. METHODS: A retrospective analysis was conducted of patients treated with the Excluder LP for infrarenal abdominal aortic aneurysm (AAA) in four hospitals between 2004 and 2017. Primary outcomes were overall survival, freedom from re-interventions (overall, inside and outside instructions for use, IFU), and AAA sac dynamics: growth (> 5 mm), stabilisation, and regression (< 5 mm). Secondary outcomes were technical success (device deployment), procedural parameters, and re-interventions. Follow up visits were extracted from patient files, with imaging assessed for complications and AAA diameter. RESULTS: Five hundred and fourteen patients were enrolled, with a median (IQR) follow up of 5.0 (2.9, 6.9) years. Survival rates were 94.0% at one year, 73.0% at five years, and 37.0% at 10 years, with freedom from re-interventions of 89.0%, 79.0%, and 71.0%, respectively. 37.9% were treated outside IFU, leading to significantly more re-interventions over 10 years compared with those treated inside IFU (36.0% vs. 25.0%, respectively; p = .044). The aneurysm sac regressed by 53.5% at one year, 65.8% at five years, and 77.8% at 10 years, and grew by 9.8%, 14.3%, and 22.2%, respectively. Patients with one year sac growth had significantly worse survival (p = .047). Seven patients (1.4%) had a ruptured aneurysm during follow up. Over 15 years, type 1a endoleak occurred in 5.3%, type 1b in 3.1%, type 3 in 1.9%, type 4 in 0.2%, and type 2 in 35.6% of patients. CONCLUSION: This multicentre study of real world endovascular aneurysm repair data using the Gore Excluder LP endoprosthesis demonstrated robust long term survival and re-intervention rates, despite 37.9% of patients being treated outside IFU, with type 4 endoleak being rare. Treatment outside IFU significantly increased re-intervention rates and one year sac growth was associated with statistically significantly worse survival.
引用
- Smorenburg SPM, de Bruin JL, Zeebregts CJ, et al. Long Term Outcomes of the Gore Excluder Low Permeability Endoprosthesis for the Treatment of Infrarenal Aortic Aneurysms. Eur J Vasc Endovasc Surg. 2024. PMID: 38527519. doi:10.1016/j.ejvs.2024.03.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。